BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 35320883)

  • 1. Posterior pelvic exenteration for ovarian cancer: surgical and oncological outcomes.
    Houvenaeghel G; de Nonneville A; Blache G; Buttarelli M; Jauffret C; Mokart D; Sabiani L
    J Gynecol Oncol; 2022 May; 33(3):e31. PubMed ID: 35320883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. En-bloc pelvic resection with concomitant rectosigmoid colectomy and immediate anastomosis as part of primary cytoreductive surgery for patients with advanced ovarian cancer.
    Yildirim Y; Ertas IE; Nayki U; Ulug P; Nayki C; Yilmaz I; Gultekin E; Dogan A; Aykas A; Ulug S; Ozdemir A; Solmaz U
    Eur J Gynaecol Oncol; 2014; 35(4):400-7. PubMed ID: 25118481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Postoperative morbidities after modified posterior pelvic exenteration for ovarian cancer].
    Emin L; Meeus P; Beurrier F; Ferraioli D; Carrabin N; Ray-Coquard I; Treilleux I; Chopin N
    Gynecol Obstet Fertil; 2015 May; 43(5):342-7. PubMed ID: 25899113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic role of mesenteric lymph nodes involvement in patients undergoing posterior pelvic exenteration during radical or supra-radical surgery for advanced ovarian cancer.
    Berretta R; Capozzi VA; Sozzi G; Volpi L; Ceni V; Melpignano M; Giordano G; Marchesi F; Monica M; Di Serio M; Riccò M; Ceccaroni M
    Arch Gynecol Obstet; 2018 Apr; 297(4):997-1004. PubMed ID: 29380107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Posterior pelvic exenteration and retrograde total hysterectomy in patients with locally advanced ovarian cancer: Clinical and functional outcome.
    Berretta R; Marchesi F; Volpi L; Ricotta G; Monica M; Sozzi G; Di Serio M; Mautone D
    Taiwan J Obstet Gynecol; 2016 Jun; 55(3):346-50. PubMed ID: 27343313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modified posterior pelvic exenteration with pelvic side-wall resection requiring both intestinal and urinary reconstruction during surgery for ovarian cancer.
    Kato K; Omi M; Fusegi A; Takeshima N
    Gynecol Oncol; 2019 Oct; 155(1):172-173. PubMed ID: 31351675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of morbidity and survival between primary and interval cytoreductive surgery in patients after modified posterior pelvic exenteration for advanced ovarian cancer.
    Revaux A; Rouzier R; Ballester M; Selle F; Daraï E; Chéreau E
    Int J Gynecol Cancer; 2012 Oct; 22(8):1349-54. PubMed ID: 22954783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
    Yao SE; Tripcony L; Sanday K; Robertson J; Perrin L; Chetty N; Land R; Garrett A; Obermair A; Nascimento M; Tang A; Jagasia N; Singh P; Nicklin J
    Int J Gynecol Cancer; 2020 Dec; 30(12):1935-1942. PubMed ID: 33122245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical characteristics and outcomes after bowel surgery and ostomy formation at the time of debulking surgery for advanced-stage epithelial ovarian carcinoma.
    Gockley AA; Fiascone S; Hicks Courant K; Pepin K; Del Carmen M; Clark RM; Goldberg J; Horowitz N; Berkowitz R; Worley M
    Int J Gynecol Cancer; 2019 Mar; 29(3):585-592. PubMed ID: 30833444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7).
    Reuss A; du Bois A; Harter P; Fotopoulou C; Sehouli J; Aletti G; Guyon F; Greggi S; Mosgaard BJ; Reinthaller A; Hilpert F; Schade-Brittinger C; Chi DS; Mahner S
    Int J Gynecol Cancer; 2019 Oct; 29(8):1327-1331. PubMed ID: 31420412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multivariate analysis of the prognostic impact of tumor burden, surgical timing and complexity after complete cytoreduction for advanced ovarian cancer.
    Angeles MA; Rychlik A; Cabarrou B; Spagnolo E; Guyon F; Pérez-Benavente A; Gil-Moreno A; Siegrist J; Querleu D; Mery E; Gladieff L; Hernández A; Ferron G; Martinez A
    Gynecol Oncol; 2020 Sep; 158(3):614-621. PubMed ID: 32709536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modified posterior pelvic exenteration for advanced ovarian malignancies: a single-institution study of 35 cases.
    Minar L; Felsinger M; Rovny I; Zlamal F; Bienertova-Vasku J; Jandakova E
    Acta Obstet Gynecol Scand; 2017 Sep; 96(9):1136-1143. PubMed ID: 28585317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy.
    Abitbol J; Gotlieb W; Zeng Z; Ramanakumar A; Kessous R; Kogan L; Pare-Miron V; Rombaldi M; Salvador S; Kucukyazici B; Brin S; How J; Lau S
    Int J Gynecol Cancer; 2019 Nov; 29(9):1341-1347. PubMed ID: 31601648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interval debulking surgery is not worth the wait: a National Cancer Database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy.
    Lyons YA; Reyes HD; McDonald ME; Newtson A; Devor E; Bender DP; Goodheart MJ; Gonzalez Bosquet J
    Int J Gynecol Cancer; 2020 Jun; 30(6):845-852. PubMed ID: 32341114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pelvic exenteration combined with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for advanced primary or recurrent colorectal cancer with peritoneal metastases.
    Brown KGM; Ansari N; Solomon MJ; Austin KKS; Hamilton AER; Young CJ
    Colorectal Dis; 2021 Jan; 23(1):186-191. PubMed ID: 32978813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surgical technique of en bloc pelvic resection for advanced ovarian cancer.
    Chang SJ; Bristow RE
    J Gynecol Oncol; 2015 Apr; 26(2):155. PubMed ID: 25872895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does sites of recurrence impact survival in secondary cytoreduction surgery for recurrent epithelial ovarian cancer?
    Kumar S; Srinivasan A; Phillips A; Madhupriya R; Pascoe J; Nevin J; Elattar A; Balega J; Cummins C; Sundar S; Kehoe ST; Singh K
    J Obstet Gynaecol; 2020 Aug; 40(6):849-855. PubMed ID: 31933417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive and Prognostic Implication of Bowel Resections During Primary Cytoreductive Surgery in Advanced Epithelial Ovarian Cancer.
    Bartl T; Schwameis R; Stift A; Bachleitner-Hofmann T; Reinthaller A; Grimm C; Polterauer S
    Int J Gynecol Cancer; 2018 Nov; 28(9):1664-1671. PubMed ID: 30371563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of postoperative morbidity on outcomes in patients with advanced epithelial ovarian cancer undergoing intestinal surgery at the time of primary or interval cytoreductive surgery: A Memorial Sloan Kettering Cancer Center Team Ovary study.
    Praiss AM; Hirani R; Zhou Q; Iasonos A; Sonoda Y; Abu-Rustum NR; Leitao MM; Long Roche K; Broach V; Gardner GJ; Chi DS; Zivanovic O
    Gynecol Oncol; 2023 Dec; 179():169-179. PubMed ID: 37992548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary cytoreductive surgery - viable treatment option in the management of platinum-sensitive recurrent ovarian cancer.
    Felsinger M; Minar L; Weinberger V; Rovny I; Zlamal F; Bienertova-Vasku J
    Eur J Obstet Gynecol Reprod Biol; 2018 Sep; 228():154-160. PubMed ID: 29957400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.